Literature DB >> 26098591

Reversal of the Transcriptome by Prostaglandin E2 during Myofibroblast Dedifferentiation.

Scott H Wettlaufer1, Jacob P Scott1, Richard C McEachin2, Marc Peters-Golden1, Steven K Huang1.   

Abstract

Myofibroblasts, the major effector cells in pathologic fibrosis, derive from the differentiation of fibroblasts driven by mediators such as transforming growth factor-β1 (TGF-β1) and biomechanical signals. Although the myofibroblast has traditionally been considered a terminally differentiated cell, the lipid mediator prostaglandin E2 (PGE2) has been shown to not only prevent but also reverse myofibroblast differentiation, as characterized by the ability of PGE2 to diminish expression of collagen I and α-smooth muscle actin in established myofibroblasts. Here, we use microarrays to examine the extent of transcriptomic changes that occur during TGF-β1-induced differentiation and PGE2-induced dedifferentiation of myofibroblasts. Normal primary human adult lung fibroblasts were cultured for 24 hours with or without TGF-β1 and treated for 48 hours with PGE2. Gene expression levels were assessed from total RNA on the Affymetrix U219 microarray. TGF-β1 up-regulated 588 genes and down-regulated 689 genes compared with control cells. PGE2 reversed the expression of 363 (62%) of the TGF-β1-up-regulated genes and 345 (50%) of the TGF-β1-down-regulated genes. Genes up-regulated by TGF-β1 and reversed by PGE2 were enriched in annotations for Cell Adhesion, Contractile Fiber, and Actin Binding, whereas genes down-regulated by TGF-β1 but subsequently reversed by PGE2 were enriched in annotations for Glycoprotein, Polysaccharide Binding, and Regulation of Cell Migration. Surprisingly, the genes whose expression was affected by PGE2 differed between TGF-β1-induced myofibroblasts and undifferentiated fibroblasts. These data demonstrate the capacity of PGE2 to effect marked global alterations in the transcriptomic program of differentiated myofibroblasts and emphasize the considerable plasticity of these cells.

Entities:  

Keywords:  fibroblasts; microarray; prostaglandin E2; pulmonary fibrosis; transforming growth factor β1

Mesh:

Substances:

Year:  2016        PMID: 26098591      PMCID: PMC4742926          DOI: 10.1165/rcmb.2014-0468OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  46 in total

Review 1.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

2.  Inhibition of protein translation as a novel mechanism for prostaglandin E2 regulation of cell functions.

Authors:  Katsuhide Okunishi; Angela J DeGraaf; Zbigniew Zasłona; Marc Peters-Golden
Journal:  FASEB J       Date:  2013-09-26       Impact factor: 5.191

3.  Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction.

Authors:  Xiangwei Huang; Naiheng Yang; Vincent F Fiore; Thomas H Barker; Yi Sun; Stephan W Morris; Qiang Ding; Victor J Thannickal; Yong Zhou
Journal:  Am J Respir Cell Mol Biol       Date:  2012-03-29       Impact factor: 6.914

4.  Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast.

Authors:  M B Vaughan; E W Howard; J J Tomasek
Journal:  Exp Cell Res       Date:  2000-05-25       Impact factor: 3.905

5.  Fibroblast growth factor reversal of the corneal myofibroblast phenotype.

Authors:  O Maltseva; P Folger; D Zekaria; S Petridou; S K Masur
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-10       Impact factor: 4.799

6.  Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation.

Authors:  Jill E Kolodsick; Marc Peters-Golden; Jose Larios; Galen B Toews; Victor J Thannickal; Bethany B Moore
Journal:  Am J Respir Cell Mol Biol       Date:  2003-05-08       Impact factor: 6.914

Review 7.  The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Kevin K Brown
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

8.  Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts.

Authors:  Thomas H Sisson; Toby M Maher; Iyabode O Ajayi; Jessie E King; Peter D R Higgins; Adam J Booth; Rommel L Sagana; Steven K Huang; Eric S White; Bethany B Moore; Jeffrey C Horowitz
Journal:  Adv Biosci Biotechnol       Date:  2012-10

9.  Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.

Authors:  Ganesh Raghu; Juergen Behr; Kevin K Brown; Jim J Egan; Steven M Kawut; Kevin R Flaherty; Fernando J Martinez; Steven D Nathan; Athol U Wells; Harold R Collard; Ulrich Costabel; Luca Richeldi; Joao de Andrade; Nasreen Khalil; Lake D Morrison; David J Lederer; Lixin Shao; Xiaoming Li; Patty S Pedersen; A Bruce Montgomery; Jason W Chien; Thomas G O'Riordan
Journal:  Ann Intern Med       Date:  2013-05-07       Impact factor: 25.391

10.  Gene expression profiling reveals novel TGFbeta targets in adult lung fibroblasts.

Authors:  Elisabetta A Renzoni; David J Abraham; Sarah Howat; Xu Shi-Wen; Piersante Sestini; George Bou-Gharios; Athol U Wells; Srihari Veeraraghavan; Andrew G Nicholson; Christopher P Denton; Andrew Leask; Jeremy D Pearson; Carol M Black; Kenneth I Welsh; Roland M du Bois
Journal:  Respir Res       Date:  2004-11-30
View more
  23 in total

Review 1.  Lipid Metabolism in Tumor-Associated Fibroblasts.

Authors:  Hongzhong Li; Jingyuan Wan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Transforming Growth Factor-β1 Increases DNA Methyltransferase 1 and 3a Expression through Distinct Post-transcriptional Mechanisms in Lung Fibroblasts.

Authors:  Hailey B Koh; Anne M Scruggs; Steven K Huang
Journal:  J Biol Chem       Date:  2016-07-12       Impact factor: 5.157

Review 3.  Molecular determinants of mesenchymal cell activation in fibroproliferative diseases.

Authors:  Loka R Penke; Marc Peters-Golden
Journal:  Cell Mol Life Sci       Date:  2019-09-28       Impact factor: 9.261

4.  Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients.

Authors:  Loubna Chadli; Britt Sotthewes; Kejie Li; Stefan N Andersen; Ellen Cahir-McFarland; Marc Cheung; Patrick Cullen; Annemarie Dorjée; Jeska K de Vries-Bouwstra; Tom W J Huizinga; David F Fischer; Jeroen DeGroot; Joanne L Viney; Timothy S Zheng; Jamil Aarbiou; Agnes Gardet
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

Review 5.  Mechanisms of Lung Fibrosis Resolution.

Authors:  Stephan W Glasser; James S Hagood; Simon Wong; Carmen A Taype; Satish K Madala; William D Hardie
Journal:  Am J Pathol       Date:  2016-03-25       Impact factor: 4.307

Review 6.  Alveolar lipids in pulmonary disease. A review.

Authors:  Christina W Agudelo; Ghassan Samaha; Itsaso Garcia-Arcos
Journal:  Lipids Health Dis       Date:  2020-06-03       Impact factor: 3.876

Review 7.  The Roles of Various Prostaglandins in Fibrosis: A Review.

Authors:  Ke Li; Jing Zhao; Mingxuan Wang; Lingzhi Niu; Yuanping Wang; Yanxia Li; Yajuan Zheng
Journal:  Biomolecules       Date:  2021-05-24

8.  GPCR-mediated YAP/TAZ inactivation in fibroblasts via EPAC1/2, RAP2C, and MAP4K7.

Authors:  Kyoung Moo Choi; Andrew J Haak; Ana M Diaz Espinosa; Katherine A Cummins; Patrick A Link; Aja Aravamudhan; David K Wood; Daniel J Tschumperlin
Journal:  J Cell Physiol       Date:  2021-05-28       Impact factor: 6.384

9.  Probing into the Mechanism of Alkaline Citrus Extract Promoted Apoptosis in Pulmonary Fibroblasts of Bleomycin-Induced Pulmonary Fibrosis Mice.

Authors:  Qi Wu; Yao Zhou; Fan-Chao Feng; Yi-Han Jin; Zhi-Chao Wang; Xian-Mei Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-26       Impact factor: 2.629

Review 10.  Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways.

Authors:  Vidyani Suryadevara; Ramaswamy Ramchandran; David W Kamp; Viswanathan Natarajan
Journal:  Int J Mol Sci       Date:  2020-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.